Related Experiment Video

Updated: May 3, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Dynamics of IGF-1R expression during endocrine breast cancer treatment

Sandra Heskamp1, Otto C Boerman, Janneke D M Molkenboer-Kuenen

  • 1Department of Nuclear Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands, sandra.heskamp@radboudumc.nl.

Molecular Imaging and Biology
|February 18, 2014
PubMed
Abstract

Insights

Endocrine therapy impacts insulin-like growth factor 1 receptor (IGF-1R) expression in breast cancer. Anti-estrogen treatments like tamoxifen can reduce IGF-1R, suggesting caution when combining therapies.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Imaging

Background:

  • Insulin-like growth factor 1 receptor (IGF-1R) plays a role in breast cancer growth.
  • Understanding IGF-1R dynamics during endocrine therapy is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate changes in IGF-1R expression using immunoSPECT/CT.
  • To investigate the dynamics of IGF-1R expression in human breast tumors during endocrine treatment.

Main Methods:

  • MCF-7 xenografts in mice were treated with estradiol or tamoxifen.
  • IGF-1R expression was assessed via immunohistochemistry and immunoSPECT/CT with (111)In-R1507.
  • Human breast tumors (n=22) treated preoperatively with endocrine therapy were analyzed.

Main Results:

  • Estradiol increased IGF-1R expression, confirmed by both methods.
  • Tamoxifen led to IGF-1R downregulation, though not detectable by immunoSPECT/CT.
  • A downregulation of IGF-1R was observed in 41% of human breast tumors post-endocrine therapy.

Conclusions:

  • Anti-estrogen therapy can decrease membranous IGF-1R expression.
  • Combining anti-IGF-1R antibodies with anti-estrogen therapy may not be a rational strategy based on these findings.

More Related Videos

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K